Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom

GAITHERSBURG, Md., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated its...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials